CurveBeam AI (ASX:CVB) Total Receivables: A$6.28 Mil (As of Dec. 2025)


What is CurveBeam AI Total Receivables?

CurveBeam AI ASX:CVB Total Receivables is A$6.28 Mil as of Dec. 2025. The stock has 5 warning signs investors should review.

CurveBeam AI's Total Receivables for the quarter that ended in Dec. 2025 was A$6.28 Mil.

CurveBeam AI Total Receivables Historical Data

* Premium members only.

The historical data trend for CurveBeam AI's Total Receivables can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CurveBeam AI Total Receivables Chart

CurveBeam AI Annual Data
Trend Jun21 Jun22 Jun23 Jun24 Jun25
Total Receivables
0.00 0.00 4.18 3.90 3.14

CurveBeam AI Semi-Annual Data
Jun21 Dec21 Jun22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Receivables Get a 7-Day Free Trial Premium Member Only 3.47 3.90 1.83 3.14 6.28

CurveBeam AI Total Receivables Calculation

Total Receivables is the sum of all receivables owed by customers and affiliates within one year, including:
Accounts Receivable
Notes Receivable
Loans Receivable
Other Current Receivables

Frequently Asked Questions Learn more about Total Receivables →
What does a Total Receivables of A$6.28 Mil mean?
CurveBeam AI (ASX:CVB) has a Total Receivables of A$6.28 Mil as of Dec. 2025. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on CurveBeam AI and its competitors.
Is CurveBeam AI's Total Receivables too high?
CurveBeam AI's current Total Receivables is A$6.28 Mil.
How does CurveBeam AI's Total Receivables compare to ABT and SYK?
CurveBeam AI's Total Receivables of A$6.28 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Receivables for a Medical Devices & Instruments company?
A good Total Receivables depends on the Medical Devices & Instruments industry context. However, Total Receivables should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Receivables mean?
A high Total Receivables can signal that a stock is expensive relative to its fundamentals. Total Receivables is the sum of all receivables owed by customers and affiliates within one year. View historical data on CurveBeam AI and its competitors. CurveBeam AI's current Total Receivables is A$6.28 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CurveBeam AI stock overvalued right now?
CurveBeam AI (ASX:CVB) has a current Total Receivables of A$6.28 Mil. The current Total Receivables is A$6.28 Mil. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Receivables calculated?
Total Receivables is calculated from a company's financial statements. For CurveBeam AI (ASX:CVB), the current Total Receivables is A$6.28 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

CurveBeam AI Business Description

Address 10 Queen Street, Level 10, Melbourne, VIC, AUS, 3000
CurveBeam AI Ltd is a manufacturer of specialized imaging equipment that has developed software that, through the use of artificial intelligence (AI), and deep learning AI (DLAI), automates the scan processing and analysis of the high-quality images produced from the company's CT devices to assist in the clinical assessment. The company has one operating segment, being the research, design, manufacture and sale of cone beam CT imaging equipment for orthopaedic specialties, which includes the development, validation and preparation for commercialisation of a HRpQCT Medical Device and Software as a Service (SaaS) platform.